Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17113559 | p53 Peptides as Markers in the Diagnosis and Prognosis of Alzheimer's Disease | December 2020 | January 2023 | Allow | 25 | 4 | 0 | Yes | No |
| 17104886 | METHODS FOR AIDING IN THE HYPERACUTE DIAGNOSIS AND DETERMINATION OF TRAUMATIC BRAIN INJURY IN A HUMAN SUBJECT USING EARLY BIOMARKERS | November 2020 | May 2024 | Allow | 41 | 2 | 0 | Yes | No |
| 17099668 | METHODS FOR AIDING IN THE DETERMINATION OF WHETHER TO PERFORM IMAGING ON A HUMAN SUBJECT WHO HAS SUSTAINED OR MAY HAVE SUSTAINED AN INJURY TO THE HEAD USING EARLY BIOMARKERS | November 2020 | May 2024 | Allow | 42 | 2 | 0 | Yes | No |
| 17095695 | METHODS FOR AIDING IN THE HYPERACUTE DIAGNOSIS AND DETERMINATION OF TRAUMATIC BRAIN INJURY USING EARLY BIOMARKERS ON AT LEAST TWO SAMPLES FROM THE SAME HUMAN SUBJECT | November 2020 | May 2024 | Allow | 42 | 2 | 0 | Yes | No |
| 17093251 | METHODS OF TREATING PRADER WILLI SYNDROME AND CONDITIONS ASSOCIATED WITH LOW BASAL METABOLIC RATE OR HYPERPHAGIA USING A KATP CHANNEL OPENER | November 2020 | October 2023 | Abandon | 35 | 1 | 0 | No | No |
| 17084568 | METHODS FOR AIDING IN DIAGNOSING AND EVALUATING A MILD TRAUMATIC BRAIN INJURY IN A HUMAN SUBJECT USING CARDIAC TROPONIN I AND EARLY BIOMARKERS | October 2020 | November 2023 | Allow | 36 | 1 | 0 | Yes | No |
| 17081013 | USE OF AKT PHOSPHORYLATION AS A BIOMARKER FOR PROGNOSING NEURODEGENERATIVE DISEASES AND TREATING SAME | October 2020 | August 2023 | Allow | 33 | 2 | 0 | No | No |
| 17080180 | METHODS OF TREATING PRADER-WILLI SYNDROME | October 2020 | December 2023 | Allow | 38 | 1 | 1 | No | No |
| 17078678 | IN VITRO DETECTION OF PRIONS | October 2020 | January 2023 | Allow | 27 | 4 | 1 | Yes | No |
| 17046116 | QUANTIFICATION OF BIOMARKERS PRESENT IN DRIED PHYSIOLOGICAL SAMPLES | October 2020 | June 2024 | Allow | 44 | 3 | 1 | Yes | No |
| 17046119 | QUANTIFICATION OF BIOMARKERS PRESENT IN PHYSIOLOGICAL SAMPLES | October 2020 | June 2024 | Allow | 44 | 3 | 1 | Yes | No |
| 16982494 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES COMPRISING COX2 ACETYLATING AGENT AS ACTIVE INGREDIENT | September 2020 | October 2023 | Allow | 37 | 2 | 1 | No | No |
| 16979822 | DETECTION OF PHOSPHO-SERINE 129 ALPHA-SYNUCLEIN IN BLOOD CELLS AS A BIOMARKER FOR SYNUCLEINOPATHIES | September 2020 | May 2023 | Abandon | 32 | 0 | 1 | No | No |
| 16978244 | DETECTION OF PATHOLOGICAL PROTEIN AGGREGATION | September 2020 | August 2023 | Allow | 35 | 2 | 1 | Yes | No |
| 17011374 | ALPHA-SYNUCLEIN DETECTION USING BEADS | September 2020 | April 2021 | Allow | 7 | 1 | 0 | No | No |
| 17005892 | NOVEL NERVOUS SYSTEM-SPECIFIC TRANSMEMBRANE PROTEASOME COMPLEX THAT MODULATES NEURONAL SIGNALING THROUGH EXTRACELLULAR SIGNALING VIA BRAIN ACTIVITY PEPTIDES | August 2020 | December 2023 | Allow | 40 | 1 | 1 | No | No |
| 16986904 | INNATE IMMUNE PROTEINS AS BIOMARKERS FOR CNS INJURY | August 2020 | August 2023 | Abandon | 36 | 1 | 1 | No | No |
| 16938736 | METHODS OF TREATING COGNITIVE IMPAIRMENT | July 2020 | November 2023 | Allow | 40 | 3 | 0 | No | No |
| 16961995 | DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDERS BASED ON AMINE CONTAINING METABOTYPES | July 2020 | March 2024 | Abandon | 44 | 1 | 0 | No | No |
| 16959990 | SEPTAPEPTIDES ASSOCIATED WITH NEURODEGENERACY | July 2020 | December 2023 | Abandon | 42 | 2 | 1 | No | No |
| 16916809 | NT-proANP AND NT-proBNP FOR THE DIAGNOSIS OF STROKE | June 2020 | March 2024 | Abandon | 45 | 3 | 1 | Yes | No |
| 16913394 | Prognostic and Diagnostic Glycan-Based Biomarkers of Brain Damage | June 2020 | December 2022 | Abandon | 30 | 1 | 1 | No | No |
| 16909881 | ANTI-HUMAN NGF ANTIBODIES AND METHODS USING SAME | June 2020 | January 2023 | Allow | 30 | 3 | 1 | No | No |
| 16904023 | DIAGNOSIS OF A NEUROAUTOIMMUNE DISEASE | June 2020 | February 2022 | Allow | 20 | 0 | 0 | No | No |
| 16893266 | BIOMARKERS AND METHODS FOR DETECTION OF SEIZURES AND EPILEPSY | June 2020 | October 2022 | Allow | 29 | 4 | 1 | Yes | No |
| 16889771 | METHODS OF ASSESSING FUTURE MEMORY LOSS BY MEASURING POLYUNSATURATED FATTY ACIDS | June 2020 | November 2022 | Abandon | 30 | 2 | 0 | Yes | No |
| 16884768 | DELTA-2-TUBULIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR PERIPHERAL NEUROPATHY | May 2020 | September 2023 | Allow | 39 | 4 | 2 | No | Yes |
| 16885102 | SCREENING METHODS USING CANINE T2R RECEPTORS AND PET FOOD PRODUCTS AND COMPOSITIONS IDENTIFIED USING THE SAME | May 2020 | May 2022 | Abandon | 23 | 3 | 0 | No | No |
| 16881052 | Method For Detecting Bodily Adhesions By Identifying Markers In Circulating Cells | May 2020 | April 2024 | Abandon | 47 | 3 | 1 | No | No |
| 16764431 | METHODS AND COMPOSITIONS FOR THE IMPROVEMENT OF LYSOSOMAL FUNCTION AND TREATMENT OF NEURODEGENERATIVE DISEASE | May 2020 | May 2022 | Abandon | 24 | 1 | 1 | No | No |
| 16762794 | METHODS FOR EVALUATING AND IMPROVING COGNITIVE FUNCTION | May 2020 | April 2024 | Allow | 47 | 3 | 1 | No | No |
| 16761350 | DENDRITIC CELL RECRUITMENT FROM BLOOD TO BRAIN IN NEURODEGENERATIVE DISEASE | May 2020 | November 2023 | Abandon | 42 | 2 | 0 | No | No |
| 16863429 | METHODS FOR TREATING INFLAMMATION | April 2020 | October 2022 | Abandon | 29 | 2 | 1 | No | No |
| 16861330 | COMPOSITIONS AND METHODS FOR TREATMENT DURING NON-ACUTE PERIODS FOLLOWING CNS NEUROLOGICAL INJURY | April 2020 | October 2022 | Allow | 30 | 2 | 0 | No | No |
| 16860713 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER | April 2020 | September 2021 | Abandon | 17 | 2 | 1 | Yes | No |
| 16860239 | TREATMENT OF MOST BOTHERSOME SYMPTOM (MBS) ASSOCIATED WITH MIGRAINE USING ANTI-CGRP ANTIBODIES | April 2020 | April 2023 | Abandon | 35 | 3 | 1 | No | No |
| 16852755 | INHIBITION OF AUTISM SPECTRUM DISORDER USING DECOY ANTIGENS TO MATERNAL BRAIN-REACTIVE ANTIBODIES | April 2020 | February 2022 | Allow | 22 | 1 | 0 | Yes | No |
| 16755303 | METHOD OF SCREENING COMPOUNDS FOR TREATING CNS DISORDERS | April 2020 | March 2024 | Abandon | 47 | 4 | 1 | No | No |
| 16846065 | GENE THERAPIES FOR LYSOSOMAL DISORDERS | April 2020 | January 2024 | Allow | 45 | 2 | 1 | No | No |
| 16840664 | TREATMENT OF MOOD AND STRESS RELATED DISORDERS | April 2020 | October 2023 | Abandon | 42 | 3 | 1 | Yes | No |
| 16753295 | USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES FOR THE TREATMENT AND DIAGNOSIS OF MOOD DISORDERS | April 2020 | April 2024 | Allow | 48 | 3 | 1 | Yes | No |
| 16651860 | METHOD OF TREATING ACUTE CORONARY SYNDROME | March 2020 | April 2024 | Allow | 48 | 4 | 1 | No | No |
| 16829917 | Serum Biomarker Screen for the Diagnosis of Clinical and Preclinical Alzheimer's Disease | March 2020 | May 2022 | Abandon | 25 | 1 | 0 | No | No |
| 16630045 | BIOMARKER FOR COGNITIVE DYSFUNCTION DISEASE AND METHOD FOR DETECTING COGNITIVE DYSFUNCTION DISEASE USING BIOMARKER | March 2020 | September 2022 | Allow | 32 | 4 | 1 | Yes | No |
| 16810319 | METHODS OF TREATING AL AMYLOIDOSIS | March 2020 | November 2022 | Abandon | 32 | 3 | 1 | Yes | No |
| 16793208 | TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES | February 2020 | December 2022 | Allow | 34 | 3 | 0 | No | No |
| 16787938 | OPTIMIZED MINI-DYSTROPHIN GENES AND EXPRESSION CASSETTES AND THEIR USE | February 2020 | March 2021 | Allow | 13 | 1 | 0 | No | No |
| 16788123 | ANTI-NEURODEGENERATIVE THERAPEUTIC, METHOD OF MANUFACTURE, AND USE | February 2020 | July 2023 | Allow | 41 | 4 | 1 | No | No |
| 16635752 | METHODS AND APPARATUS FOR DETERMINING RISK OF AUTISM SPECTRUM DISORDER | January 2020 | September 2024 | Abandon | 55 | 5 | 1 | Yes | No |
| 16779229 | PREDICTING SUICIDALITY USING A COMBINED GENOMIC AND CLINICAL RISK ASSESSMENT | January 2020 | November 2021 | Abandon | 22 | 0 | 1 | No | No |
| 16775811 | IPTG-FREE INDUCTION PROCESS FOR EXPRESSION OF BIOSIMILAR RHU RANIBIZUMAB ANTIBODY FRAGMENT USING E. COLI | January 2020 | October 2022 | Allow | 32 | 3 | 0 | Yes | No |
| 16736937 | TREATMENT OF MEDICATION OVERUSE HEADACHE USING ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES | January 2020 | February 2024 | Abandon | 49 | 5 | 1 | Yes | No |
| 16736925 | ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES | January 2020 | December 2022 | Allow | 35 | 3 | 1 | Yes | No |
| 16733663 | GPR156 Variants And Uses Thereof | January 2020 | June 2021 | Allow | 18 | 2 | 0 | No | Yes |
| 16726427 | COMPOSITIONS AND METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS USING AN ENDOTHELIN-B RECEPTOR AGONIST | December 2019 | November 2023 | Abandon | 46 | 4 | 1 | No | No |
| 16716095 | ASTROCYTE TRAUMATOME AND NEUROTRAUMA BIOMARKERS | December 2019 | October 2021 | Allow | 22 | 2 | 0 | Yes | No |
| 16713425 | MULTI-PROTEIN BIOMARKER ASSAY FOR BRAIN INJURY DETECTION AND OUTCOME | December 2019 | August 2022 | Allow | 33 | 3 | 1 | Yes | No |
| 16622287 | IL-10, S100B AND H-FABP MARKERS AND THEIR USE IN DETECTING TRAUMATIC BRAIN INJURY | December 2019 | May 2023 | Abandon | 41 | 1 | 1 | No | No |
| 16700750 | COMPOSITIONS AND METHODS FOR NEURALGENESIS | December 2019 | December 2022 | Allow | 37 | 4 | 1 | Yes | No |
| 16618262 | BIOMARKER FOR ALZHEIMER'S DISEASE | November 2019 | August 2022 | Abandon | 32 | 2 | 1 | Yes | No |
| 16698363 | MARKERS AND THEIR USE IN BRAIN INJURY | November 2019 | April 2022 | Abandon | 29 | 2 | 1 | Yes | No |
| 16695717 | METHODS FOR DIAGNOSING HUNTINGTON�S DISEASE | November 2019 | August 2023 | Abandon | 44 | 5 | 0 | Yes | No |
| 16696941 | MEMORY IN SUBJECTS WITH MINI-MENTAL STATE EXAMINATION OF 24-26 | November 2019 | March 2022 | Allow | 28 | 2 | 1 | No | No |
| 16693461 | MUTANT PROTEINS AND METHODS FOR THEIR PRODUCTION | November 2019 | October 2022 | Abandon | 34 | 2 | 1 | No | No |
| 16615044 | COMPOSITIONS AND METHODS FOR IMPROVING COGNITION | November 2019 | October 2023 | Abandon | 47 | 5 | 0 | Yes | No |
| 16688650 | ANIMAL MODEL OF A MOOD DISORDER AND SCREENING METHOD | November 2019 | August 2022 | Abandon | 33 | 2 | 1 | No | No |
| 16685041 | METHOD FOR PRODUCING REFOLDED RECOMBINANT HUMANIZED RANIBIZUMAB | November 2019 | August 2022 | Allow | 33 | 3 | 0 | Yes | No |
| 16685149 | BIOMARKERS AND METHODS FOR DETECTION OF SEIZURES AND EPILEPSY | November 2019 | February 2023 | Allow | 39 | 4 | 1 | No | No |
| 16677414 | PRECISION MEDICINE FOR TREATING AND PREVENTING SUICIDALITY | November 2019 | October 2022 | Allow | 35 | 4 | 1 | Yes | No |
| 16610428 | BLOOD-BASED METHODS FOR DETERMINING A-BETA AMYLOIDOSIS | November 2019 | April 2024 | Allow | 53 | 5 | 0 | Yes | No |
| 16609914 | METHOD FOR DIAGNOSIS OF UNSTABLE ATHEROSCLEROTIC PLAQUES | October 2019 | October 2022 | Abandon | 36 | 0 | 1 | No | No |
| 16669629 | BIOMARKER FOR DIAGNOSING DEPRESSION AND USE OF BIOMARKER | October 2019 | August 2020 | Abandon | 9 | 0 | 0 | No | No |
| 16669626 | 5-HYDROXYTRYPTAMINE 1B RECEPTOR-STIMULATING AGENT FOR USE AS A PROMOTER OF SATELLITE CELLS SELF-RENEWAL AND/OR DIFFERENTIATION | October 2019 | February 2022 | Allow | 27 | 1 | 0 | No | No |
| 16661769 | METHODS FOR REDUCING POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) | October 2019 | August 2021 | Allow | 22 | 2 | 1 | Yes | No |
| 16658439 | SCREENING METHOD | October 2019 | November 2021 | Allow | 24 | 2 | 0 | No | No |
| 16606727 | CD 14 ANTAGONIST ANTIBODIES FOR TREATING NEURODEGENERATIVE DISEASES | October 2019 | January 2022 | Abandon | 27 | 2 | 1 | No | No |
| 16575248 | INHIBITION OF ALPHA5BETA1 INTEGRIN WITH ATN-161 AS A NOVEL THERAPY FOR VASCULAR DEMENTIA | September 2019 | June 2023 | Abandon | 45 | 5 | 1 | Yes | No |
| 16492115 | METHOD OF IDENTIFYING MALODOR MODULATING COMPOUNDS | September 2019 | May 2023 | Allow | 45 | 4 | 1 | No | No |
| 16489426 | METHOD OF DIAGNOSIS OF DRUG INDUCED LIVER INJURY | August 2019 | January 2024 | Allow | 52 | 3 | 1 | Yes | No |
| 16489506 | A NOVEL NERVOUS SYSTEM-SPECIFIC TRANSMEMBRANE PROTEASOME COMPLEX THAT MODULATES NEURONAL SIGNALING THROUGH EXTRACELLULAR SIGNALING VIA BRAIN ACTIVITY PEPTIDES | August 2019 | June 2023 | Abandon | 45 | 2 | 1 | No | No |
| 16488011 | HEXOKINASE 2-SPECIFIC INHIBITORS FOR USE IN ACUTE CENTRAL NERVOUS SYSTEM INJURY | August 2019 | October 2022 | Allow | 38 | 3 | 1 | Yes | No |
| 16487332 | SEROLOGIC ASSAY FOR SILENT BRAIN ISCHEMIA | August 2019 | September 2023 | Abandon | 49 | 2 | 1 | Yes | No |
| 16544383 | DIAGNOSTIC DRUG AND DIAGNOSTIC METHOD FOR ALZHEIMER'S DISEASE | August 2019 | March 2024 | Abandon | 55 | 8 | 0 | Yes | No |
| 16486687 | METHODS AND COMPOSITIONS FOR TREATING A BRAIN INJURY | August 2019 | July 2021 | Abandon | 23 | 1 | 1 | No | No |
| 16539829 | BIOMARKER FOR MENTAL DISORDERS INCLUDING COGNITIVE DISORDERS, AND METHOD USING SAID BIOMARKER TO DETECT MENTAL DISORDERS INCLUDING COGNITIVE DISORDERS | August 2019 | March 2023 | Allow | 43 | 5 | 1 | Yes | No |
| 16484272 | ASSAY FOR PHAGOCYTIC IMMUNE CELL DEFECTS ASSOCIATED WITH AUTISM | August 2019 | May 2021 | Abandon | 22 | 1 | 1 | No | No |
| 16534098 | METHODS, SYSTEMS AND COMPOSITIONS FOR WHOLE BRAIN PROTEOME-BASED TRAUMATIC BRAIN INJURY (TBI) AND ASSOCIATED NEURODEGENERATIVE DISEASE IMMUNE RESPONSE DIAGNOSTICS | August 2019 | August 2022 | Abandon | 36 | 3 | 0 | Yes | No |
| 16484073 | ERYTHROCYTE-DERIVED EXTRACELLULAR VESICLES AND PROTEINS ASSOCIATED WITH SUCH VESICLES AS BIOMARKERS FOR PARKINSON'S DISEASE | August 2019 | January 2023 | Allow | 41 | 2 | 1 | No | No |
| 16483260 | METABOLIC BIOMARKERS FOR COGNITIVE ABILITY | August 2019 | November 2021 | Allow | 27 | 2 | 1 | No | No |
| 16481245 | NEUROTROPHIN MUTANTS FOR TREATING HEARING LOSS AND OTHER OTIC DISORDERS | July 2019 | January 2023 | Abandon | 42 | 2 | 1 | Yes | No |
| 16481312 | NEUROTROPHIN MUTANTS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | July 2019 | April 2022 | Abandon | 33 | 0 | 1 | No | No |
| 16477812 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING PEROXISOMAL DISEASES | July 2019 | January 2024 | Allow | 54 | 2 | 1 | No | No |
| 16474814 | BIOSENSOR EXHIBITING SENSITIVITY TO TRINITROTOLUENE | June 2019 | October 2021 | Allow | 28 | 2 | 1 | No | No |
| 16473256 | METHOD FOR MODIFYING THE THERAPEUTIC EFFECTS OF DRUGS | June 2019 | September 2023 | Abandon | 50 | 6 | 0 | Yes | No |
| 16436867 | Compositions and Methods for Uncoupling TrkB Receptor from PLC Gamma 1 for the Treatment of Epilepsy and Anxiety-Like Disorder | June 2019 | May 2021 | Allow | 23 | 2 | 1 | No | No |
| 16435483 | DIAGNOSTIC AUTOANTIBODY PROFILES FOR THE DETECTION AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES | June 2019 | July 2022 | Allow | 37 | 4 | 1 | Yes | No |
| 16467783 | METHODS OF DIAGNOSING ALZHEIMER'S DISEASE AND RISK OF PROGRESSION TO ALZHEIMER'S DISEASE | June 2019 | March 2023 | Allow | 45 | 3 | 1 | No | No |
| 16433106 | CITRULLINATED BRAIN AND NEUROLOGICAL PROTEINS AS BIOMARKERS OF BRAIN INJURY OR NEURODEGENERATION | June 2019 | February 2024 | Allow | 56 | 8 | 0 | Yes | Yes |
| 16432483 | THERAPY OF IONIZING RADIATION-INDUCED DISORDERS | June 2019 | January 2023 | Abandon | 44 | 4 | 1 | Yes | No |
| 16431559 | CIRCULATING ASTROCYTES AND MFSD2A AS BIOMARKERS | June 2019 | March 2021 | Allow | 21 | 2 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHERNYSHEV, OLGA N.
With a 29.4% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 16.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner CHERNYSHEV, OLGA N works in Art Unit 1649 and has examined 955 patent applications in our dataset. With an allowance rate of 35.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner CHERNYSHEV, OLGA N's allowance rate of 35.4% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CHERNYSHEV, OLGA N receive 2.30 office actions before reaching final disposition. This places the examiner in the 61% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by CHERNYSHEV, OLGA N is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +47.0% benefit to allowance rate for applications examined by CHERNYSHEV, OLGA N. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 15.6% of applications are subsequently allowed. This success rate is in the 14% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 37.5% of cases where such amendments are filed. This entry rate is in the 58% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 47.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 42% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 76.1% of appeals filed. This is in the 67% percentile among all examiners. Of these withdrawals, 61.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 63.5% are granted (fully or in part). This grant rate is in the 66% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 2.3% of allowed cases (in the 76% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.8% of allowed cases (in the 69% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.